Product Description
Introduction
The Turkish generics market saw sales of $3.4bn in 2010, and has a high growth potential, driven by Turkish generics players' successes in international markets, good manufacturing practice which assists local players, intellectual property laws allowing the earlier launch of generics compared to other European markets, and pharmacist substitution.
Features And Benefits
• Insight into the key drivers and resistors to generics uptake in Turkey.
• Assesses strategies employed by the leading generics companies operating in Turkey.
• Analyses biosimilar opportunities in Turkey and factors which could drive or restrict future uptake.
Highlights
Currently there are no biosimilar products marketed in Turkey. Nevertheless, in 2008 Turkey introduced a biosimilar pathway, which together with favourable data exclusivity requirements could allow prospective biosimilar players a swift market entry.
The fact that all drugs marketed in Turkey require a Turkish good manufacturing practice (GMP) certificate benefits domestic generics players by delaying entry for international generics companies.
A number of Turkish generics companies have entered into agreements with foreign biosimilars players. This circumvents the limited R&D capacity of Turkish manufacturers which restricts the opportunity for a domestically developed biosimilar entering the market anytime soon.
Your Key Questions Answered
• What are the drivers and resistors to generic uptake in Turkey?
• What deal types are companies entering into when looking to enter or bolster their position in the Turkish generics and biosimilars market?
• Which branded biologics and small molecules are facing patent expiry in Turkey?
Table of Contents
Executive Summary
Turkey - Introduction
Turkey - Strategic scoping and focus
Turkey - Key findings
Generics market
Biosimilars market
Related reports
TURKEY - GENERICS MARKET OVERVIEW
Turkey - Generics market dynamics
Turkey generics volume uptake
Turkey generics value uptake
Turkey generics market size
Turkey - Generics drivers and resistors
Drug registration delays and GMP practices assist local players
Low pharmaceutical spend per capita limits generics market size
Turkey references prices from countries with some of the lowest drug prices in Europe
Price cuts in Europe negatively impact generic prices in Turkey
Further social security discounts introduced in December 2010 impact generics margins further
Branding is the key to success in Turkey
Pharmacist substitution assists generic uptake
IP laws allow the earlier launch of generics
Turkey - Key generics players
Abdi Ibrahim looks to international markets to cement its strong position in Turkey
Eczacıbaşı Pharmaceuticals (owned by Zentiva) is the second largest generics producer in Turkey
Deva Holdings extends its presence in Turkey
Sandoz maintains a significant market presence in Turkey
TURKEY - BIOSIMILARS MARKET OVERVIEW
Turkey - Drivers of biosimilar uptake
Turkey has a biosimilar pathway in place
Data exclusivity requirements favor biosimilars producers
A major agreement will see biosimilars enter Turkey
Nobel to market erythropoietin zeta
Inadequate R&D investment likely to prevent Turkish generics producers turning to biosimilars
Turkey - Opportunities for the biosimilar industry
Biosimilar MAbs and second-generation biosimilars offer the greatest commercial potential
TURKEY - BIBLIOGRAPHY
Publications and online articles
Datamonitor reports
Appendix
Exchange rates used in this report
About Datamonitor
